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Abstract
Background: The rapid desensitization of the human prostacyclin (IP) in response to agonist
binding has been shown in cell culture. Phosphorylation of the IP receptor by protein kinase C
(PKC) has been suggested to be involved in this process.
Methods and results: In this study we investigated the vasodilatory effects of iloprost, a stable
prostacyclin analogue, in perfused rabbit lungs. Continuous infusion of the thromboxane mimetic
U46619 was employed to establish stable pulmonary hypertension. A complete loss of the
vasodilatory response to iloprost was observed in experiments with continuous iloprost perfusion,
maintaining the intravascular concentration of this prostanoid over a 180 min period. When lungs
under chronic iloprost infusion were acutely challenged with inhaled iloprost, a corresponding
complete loss of vasoreactivity was observed. This desensitization was not dependent on
upregulation of cAMP-specific phosphodiesterases or changes in adenylate cyclase activity, as
suggested by unaltered dose-response curves to agents directly affecting these enzymes.
Application of a prostaglandin E1 receptor antagonist 6-isopropoxy-9-oxoxanthene-2-carboxylic
acid (AH 6809) or the PKC inhibitor bisindolylmaleimide I (BIM) enhanced the vasodilatory
response to infused iloprost and partially prevented tachyphylaxis.
Conclusion: A three-hour infusion of iloprost in pulmonary hypertensive rabbit lungs results in
complete loss of the lung vasodilatory response to this prostanoid. This rapid desensitization is
apparently not linked to changes in adenylate cyclase and phosphodiesterase activation, but may
involve PKC function and co-stimulation of the EP1 receptor in addition to the IP receptor by this
prostacyclin analogue.
Published: 26 January 2007
Respiratory Research 2007, 8:4 doi:10.1186/1465-9921-8-4
Received: 24 February 2006
Accepted: 26 January 2007
This article is available from: http://respiratory-research.com/content/8/1/4
© 2007 Schermuly et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
Page 2 of 13
(page number not for citation purposes)
Background
Prostacyclin (PGI2) is the major product of cyclooxygen-
ases (COX) in the vascular endothelium and mediates
potent anti-platelet, vasodilator, and anti-inflammatory
actions by a prostacyclin receptor (IP) [1]. This receptor is
a member of the G protein-coupled receptor (GPCR)
superfamily and is coupled to adenylate cyclase (AC) and
phospholipase C (PLC) [2-4]. The prostanoid receptors
are classified into DP, IP, EP (EP 1–4), FP and TP receptors
[5-7] with different affinities for agonists and different
roles in signal transduction. The IP, EP2, EP4 and DP
receptors are coupled to stimulation of adenylate cyclase,
while the TP, EP1 and FP receptors are coupled to Ca2+
mobilization. The EP3 receptor is an alternative spliced
gene, with at least 8 isoforms identified so far. Depending
on the subtype, this receptor can be negatively or posi-
tively coupled to Gs [8,9]. Agonist (PGI2 or PGI2 mimetics
such as cicaprost, iloprost, carbacyclin, and prostaglandin
E1)-binding to the IP receptor leads to activation of pro-
tein kinase A (PKA) by cyclic adenosine monophosphate
(cAMP) [10]. Although, the above mentioned agonist spe-
cificities for IP receptors vary and none of them were
highly selective for IP receptors alone. The affinity of cic-
aprost for human IP receptors is merely 3-fold higher than
for the prostaglandin E2 EP4 subtype of receptor, which
also couples to Gs [11], and only 17-fold higher than for
the EP3 receptor in the mouse [12]. Iloprost is equipotent
at both human and mouse IP and EP1 receptors, and car-
bacyclin and prostaglandin E1 show even greater affinity
for EP3 than for IP receptors [11,12].
Disturbances to PGI2 synthesis [13,14], as well as poly-
morphisms of the PGI2-synthase (PGIS) [15], have been
linked to severe pulmonary hypertension. Substitution of
PGI2, either by overexpression of the PGIS [16] in an
experimental model or by application of PGI2 [17,18] or
its analogues iloprost [19,20] or beraprost [21,22] in
patients decreases pulmonary artery pressure. However,
tolerance of the lung vasodilatory response to continu-
ously infused PGI2  rapidly develops in patients with
severe pulmonary hypertension, and dose adjustments
have to be made [17,23]. In COPD patients with pulmo-
nary hypertension, the pulmonary vasodilatory response
to continuously infused PGI2  was found to dissipate
within 24 h [24]. Marked tolerance to the anti-mitogenic
actions of PGI2 developed within 24 h in coronary artery
smooth muscle cells [25]. Basic studies demonstrated that
desensitization of the IP receptor occurs within minutes
after exposure to agonists and is due to agonist-induced
receptor phosphorylation, mainly mediated by PKC [26],
with subsequent sequestration of the intact receptor and
removal from the cell surface [26,27]. In addition, there is
evidence for changes in adenylate cyclase and phosphodi-
esterase (PDE) activation occurring in response to IP
receptor stimulation, which may contribute to loss of the
vasodilatory response to PGI2 and its analogues [28-30].
In the present study, we employed the model of pulmo-
nary hypertensive perfused rabbit lungs to investigate the
dose-response relationship and features of tolerance
development upon continuous iloprost infusion in the
intact lung vasculature.
Materials and methods
Materials
Sterile Krebs-Henseleit buffer (KHB) was obtained from
Serag-Wiessner (Naila, Germany). The thromboxane-A2
mimetic U46619 was supplied by Paesel-Lorei (Frankfurt,
Germany) and iloprost by Schering (Berlin, Germany). All
other chemicals were purchased from Merck (Darmstadt,
Germany).
Isolated lung model
The perfused rabbit lung model has previously been
described in detail [31]. Briefly, rabbits of either sex
weighing 2.6 to 2.9 kg were anticoagulated with heparin
(1000 U/kg) and anaesthetized with intravenous keta-
mine/xylazine. Tracheostomy was performed and the ani-
mals were ventilated with room air. After mid-sternal
thoracotomy, catheters were placed into the pulmonary
artery and the left atrium, and perfusion with KHB was
started. For washout of blood, perfusate was initially not
recirculated and the lungs were removed without inter-
ruption of ventilation and perfusion. The lungs were
placed in a temperature-equilibrated chamber at 37.5°C,
freely suspended from a force transducer for monitoring
of organ weight. In a recirculating system the flow was
slowly increased to 120 ml/min (total volume 350 ml).
Left atrial pressure was set at 2 mmHg in all experiments.
In parallel with onset of artificial perfusion, an air mixture
of 80.5% N2, 15% O2 and 4.5% CO2 was used for ventila-
tion. Tidal volume (11 ml/kg) and frequency (10 – 13
breaths/min) were adapted to maintain the pH of the
recirculating buffer in the range between 7.35 and 7.37. A
positive end-expiratory pressure of 1 mmHg was used
throughout. The PO2 and PCO2 values in the post-lung
buffer fluid ranged between 100 and 120 mmHg and 38
and 43 mmHg, respectively. Pressures in the pulmonary
artery, the left atrium and the trachea were registered by
means of small diameter tubing threaded into the per-
fusion catheters and the trachea and connected to pressure
transducers (zero referenced at the hilum). The whole sys-
tem was heated to 37.5°C.
Lungs included in the study had 1) a homogeneous white
appearance with no signs of hemostasis, edema or atel-
ectasis; 2) pulmonary artery and ventilation pressures in
the normal range; and were 3) isogravimetric (lung weight
gain < 0.2 g/h) during an initial steady state period of at
least 45–60 min.Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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Experimental protocols
Isolated lung experiments
As described previously [32], a sustained increase of PPA
from ≈6 to ≈24 mmHg was achieved by continuous infu-
sion of the thromboxane-mimetic U46619 with a dose
range of 70–160 pmol·kg-1·min-1. Individual titration
was performed. This level of pulmonary hypertension was
then maintained for at least 320 min with variations in
PPA of less than 2 mmHg. The following experimental
groups were employed:
Control lungs (n = 4): No interventions were undertaken.
U46619-infused lungs (n = 4): After termination of the
steady state period, U46619 was continuously infused for
320 min to provoke an increase in PPA to ~24 mmHg.
Iloprost infusion (n = 4): U46619 was administered as
described. 20 min after onset of U46619 infusion, ilo-
prost was applied by a bolus injection of 200 ng, followed
by a continuous infusion of 33 ng/kg/h to achieve stable
buffer concentrations in the range of 350 pg/ml.
Intravenous PGI2 application (n = 4): U-46619 was admin-
istered as described. 20 min after onset of U-46619 infu-
sion, PGI2 was continuously applied at a dose of 50 ng·
kg-1·min-1 until termination of the experiments.
Rolipram i.v. (n = 4): After adjusting stable pulmonary
hypertension, the PDE4 inhibitor rolipram was applied in
increasing doses (dose range 0.001–10 μM).
Iloprost infusion and rolipram i.v. (n = 4): Iloprost was
applied by a bolus injection of 200 ng, followed by a con-
tinuous infusion of 33 ng/kg/h. 240 min after starting the
iloprost infusion, rolipram was applied in increasing
doses (dose range 0.001–10 μM).
Motapizone i.v. (n = 4): After adjusting stable pulmonary
hypertension, the PDE3 inhibitor motapizone was
applied in increasing doses (dose range 0.01–100 μM).
Iloprost infusion and motapizone i.v. (n = 4): Iloprost was
applied by a bolus injection of 200 ng, followed by a con-
tinuous infusion of 33 ng/kg/h. 240 min after starting the
iloprost infusion, motapizone was applied in increasing
doses (dose range 0.01–100 μM).
Iloprost inhalation (n = 4): When stable pulmonary hyper-
tension was achieved, iloprost was nebulized (deposited
dose 75 ng) by means of an ultrasonic nebulizer as
described previously [33,34].
Iloprost infusion and iloprost inhalation (n = 4): U46619 was
continuously infused and iloprost was applied by a bolus
injection of 200 ng, followed by a continuous infusion of
33 ng/kg/h. 240 min after starting the iloprost infusion,
iloprost was nebulized (deposited dose 75 ng).
Forskolin i.v. (n = 4): After adjusting stable pulmonary
hypertension, the adenylate cyclase stimulator forskolin
was applied in increasing doses (dose range 10–100 μM).
Iloprost infusion and forskolin i.v. (n = 4): Iloprost was
applied by a bolus injection of 200 ng, followed by a con-
tinuous infusion of 33 ng/kg/h. 240 min after starting the
iloprost infusion, forskolin was applied in increasing
doses (dose range 10–100 μM).
Bisindolylmaleimide I (BIM) infusion (n = 4): BIM (1 μM)
was applied by a bolus injection after stable adjustment of
pulmonary hypertension with U46619. As described pre-
viously, stable buffer levels of BIM are achieved by a single
application in the setup of isolated perfused rabbit lungs
[35].
Iloprost infusion in presence of BIM (n = 4): U46619 was
administered as described. After stable adjustment of pul-
monary hypertension, BIM (1 μM) was applied by a bolus
injection. Iloprost was bolus injected and infused as
described above.
6-isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809)
infusion (n = 4): AH 6809 (3 μM) was applied by a bolus
injection after stable adjustment of pulmonary hyperten-
sion with U46619. As described previously, AH6809 dem-
onstrated long acting EP1 blocking activity in fluid
perfused small intestine segments after a single applica-
tion [36].
Iloprost infusion in presence of AH 6809 (n = 4): U46619 was
administered as described. 45 min after onset of U46619
infusion, AH 6809 (3 μM) was applied as a bolus injec-
tion and the bolus injection plus infusion of iloprost was
started as in the preceding groups.
Cell culture
Rabbit pulmonary smooth muscle cells (PSMC) were pre-
pared as described. Primary SMC were isolated from rab-
bit pulmonary artery by carefully preparing <1 mm3
pieces of media, devoid of adventitial tissue as assessed by
microscopic control. The pieces of media were placed into
12-well cell culture plates with 500 μl culture medium.
The isolated pulmonary smooth muscle cells (PSMC)
identity was verified by characteristic appearance in
phase-contrast microscopy, indirect immunofluorescent
antibody staining for smooth muscle-specific isoforms of
α-actin and myosin (at least 95% of cells stained positive),
and lack of staining for von Willebrand factor and vimen-
tin, indicating that the cultures did not contain significantRespiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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numbers of endothelial cells or adventitial fibroblasts
[37]. Smooth muscle cells were grown in Dulbecco's mod-
ified Eagle's high glucose medium supplemented with
10% fetal bovine serum, 100 μg/ml streptomycin and 100
units/ml penicillin.
Desensitization assays and cAMP measurement
Smooth muscle cells were grown to 90% confluence in
24-well plates, as previously described. For desensitiza-
tion assays, cells were treated with iloprost for the indi-
cated times. Then, cells were washed three times with
HBSS and preincubated in HBSS containing 1 mg/ml BSA,
10 mM HEPES (pH 7.3) and 1 mM IBMX for 10 min at
37°C. Afterwards cells were again stimulated with iloprost
(100 nM) or forskolin (10 μM) for 10 min and cAMP
measurements were performed as described below. Reac-
tions were stopped by aspiration and addition of ice-cold
96% ethanol. Dried samples were overlaid with 300 μl
RIA-buffer (150 mM NaCl, 8 mM Na2HPO4, 2 mM
NaH2PO4, pH 7.4) and frozen overnight at -80°C. cAMP
in the supernatant was determined by radioimmunoassay
[Steiner et al., 1972]. Protein determination was per-
formed according to the method of Bradford. Cells treated
with vehicle alone (no ligand) or forskolin (50 μM) were
served as negative and positive controls respectively for
the cAMP measurement.
Data analysis
Values are means ± SEM. Student's t-test was performed
for comparison of two values. For multiple comparisons,
ANOVA was followed by post hoc test (Bonferroni/Dunn
method). Statistical significance was considered at p <
0.05.
Results
Baseline conditions
After termination of the steady state period, all lungs dis-
played PPA values in the range between 5 and 7 mmHg.
U46619-elicited pulmonary hypertension
Continuous infusion of U46619 provoked an increase in
PPA to 23.4 ± 0.9 mmHg within 25 min, with subsequent
plateau of the pulmonary hypertension. This level of pul-
monary hypertension was then maintained for at least
300 min with variations in PPA of less than 2 mmHg. Total
weight gain at the end of the experiments was 6.5 ± 2.7 g.
U46619-elicited pulmonary hypertension and infusion of 
iloprost or PGI2
As in the preceding group, U46619 infusion for establish-
ing stable pulmonary hypertension was performed. Bolus
injection of 200 ng iloprost was followed by an infusion
of 33 ng iloprost per hour. This procedure resulted in a
significant vasodilatory response with PPA values decreas-
ing by a mean of 3.3 mmHg. Similarly, the continuous
infusion of a more selective IP receptor ligand, PGI2 also
resulted in significant vasodilatory responses (Fig 1). Sta-
ble iloprost buffer concentrations in the range of 350–380
pg/ml were documented over the entire perfusion period.
A slow increase in PPA toward pre-infusion values was
noted to commence after 100–120 min, and 200 min
after beginning of the iloprost infusion, the vasodilatory
effect was virtually fully lost. The total weight gain of the
lungs was 5.3 ± 3.2 g, and thus did not differ from the
groups with mono U46619 infusion.
Dose-effect curves of PDE-inhibitors with or without 
infusion of iloprost
As shown in Fig. 2A, the intravascular administered PDE3
inhibitor motapizone (dose range 0.01–100 μM) effected
a dose-dependent reduction of the elevated PPA values in
lungs with U46619-elicited pulmonary hypertension.
There was no shift in the dose response curve when apply-
ing identical doses of motapizone 240 min after onset of
iloprost infusion. Similar experiments were performed
with the PDE4 inhibitor rolipram, which dose-depend-
ently reduced pulmonary artery pressure in U46619 pre-
constricted lungs, with identical dose-effect curves in the
absence and presence of iloprost infusion (Fig. 2B). Total
weight gain was 5.7 ± 2.9 g and 5.3 ± 1.9 g (iloprost infu-
sion) in the motapizone treated lungs and 4.6 ± 2.2 g and
5.0 ± 2.6 g (iloprost infusion) in the rolipram treated
lungs, respectively.
Nebulization of iloprost
Inhalation of aerosolized iloprost (total dose 75 ng
inhaled over 10 min) resulted in a significant reduction of
the U46619-induced pulmonary hypertension, with PAP
values decreasing by a mean of 6.3 mmHg (Fig. 3). In sep-
arate experiments, iloprost was infused in advance for 240
min, and then nebulization was started. There was virtu-
ally no response to inhaled iloprost after this preceding
iloprost infusion period. The total weight gain of the lungs
was 6.7 ± 2.9 g at the end of experiments.
Dose-effect curves of forskolin
As shown in Fig. 4, the adenylate cyclase activator forsko-
lin (dose range 10–300 μM) reduced the U46619-elicited
pulmonary hypertension in a dose dependant manner.
After iloprost infusion for 240 min, an identical dose
response curve was observed. Total weight gain was 5.6 ±
2.1 g at the end of the experiments.
Infusion of iloprost: effects of BIM
As in the preceding groups, U46619 infusion for estab-
lishing stable pulmonary hypertension was performed.
Subsequently, the PKC inhibitor BIM at a dose of 1 μM
was applied alone or in combination with iloprost. In
combination group, after 5 min of BIM application, bolus
injection of 200 ng iloprost was followed by an infusionRespiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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of 33 ng iloprost per hour. This procedure resulted in a
significant vasodilatory response with PPA values decreas-
ing by a mean of 4.3 mmHg (Fig. 5A). However, the sole
BIM application demonstrated no effects on U46619-elic-
ited pulmonary hypertension (Fig. 5A). The calculated
area under the curve (AUC) of the pressure curve was sig-
nificantly increased as compared to sole iloprost infusion
(Fig. 6). The loss of the vasodilatory response to iloprost
was somewhat retarded, but not prevented, as compared
to single iloprost application. The total weight gain of the
lungs was 5.8 ± 2.5 g.
Infusion of iloprost: effects of AH 6809
After adjusting stable pulmonary hypertension, the EP1
receptor antagonist AH 6809 at a dose of 3 μM was
applied alone or in combination with iloprost, without
effecting pulmonary artery pressure. In combination
group, after 5 min of AH 6809 application, a bolus injec-
tion of 200 ng iloprost was followed by an infusion of 33
ng iloprost per hour. The maximum vasodilatory response
to iloprost was 11.4 mmHg (Fig. 5B) and the area under
the curve (AUC) of the pressure curve was 305 mmHg ×
min (p < 0.05 versus sole iloprost infusion) (Fig. 6). The
total weight gain of the lungs was 4.8 ± 2.0 g. In contrary,
the AH 6809 application alone had no effect on U46619-
induced tension (Fig. 5B).
Measurement of cyclic AMP
We assayed the desensitization kinetics of iloprost and
forskolin in rabbit pulmonary smooth muscle cells (Fig.
Prostacyclin receptor (IP) desensitization in U46619-induced pulmonary hypertension in intact rabbit lungs in response to PGI2  or iloprost infusion Figure 1
Prostacyclin receptor (IP) desensitization in U46619-induced pulmonary hypertension in intact rabbit lungs in 
response to PGI2 or iloprost infusion. Pulmonary hypertension was adjusted by continuous infusion of the thromboxane 
mimetic U46619. After a bolus injection of 200 ng iloprost followed by an infusion of 33 ng iloprost per hour (stable buffer lev-
els of ~350 pg/ml) or continuous infusion of PGI2 (50 ng/min) is administered and measured their influence on U46619-elicited 
pulmonary hypertension.Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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7). Incubation of cells with iloprost led to a time-depend-
ent reduction of iloprost induced cAMP formation to 88%
(1 h), 71% (2 h), 76% (3 h), 66% (5 h), 54% (7 h) and
26% (24 h) of control. Incubation of cells with iloprost
and stimulation of cells with forskolin led to a reduction
of cAMP formation to 83% (1 h), 84% (2 h), 91% (3 h),
83% (5 h), 79% (7 h) and 75% (24 h) of control.
Discussion
The desensitization of the IP receptor after incubation of
platelets [38,39] or IP receptor overexpressing cells
[26,27,40,41] with PGI2 or its analogues in vitro is a well-
known phenomenon. Tolerance development of the lung
vasodilatory response to PGI2 has also been observed in
patients with severe pulmonary hypertension being
chronically treated by intravenous infusion of the prosta-
noid [23,24]. In the present study we show that such
desensitization occurs within 180 min in perfused rabbit
lungs.
Desensitization is not dependant on increased PDE activity
Phosphodiesterases (PDE) are enzymes that hydrolyze
cyclic AMP and cyclic GMP, the second messengers of
PGI2, and NO [42,43]. The characterization of the various
PDEs currently known has profited from the employment
of selective PDE inhibitors. Concerning the lung vascula-
ture, the presence of the PDE isoenzymes 1, 3, 4 and 5 in
the cytosolic and particulate phases (homogenized
Dose effect curve of the PDE3 inhibitor motapizone or PDE4 inhibitor rolipram on U46619-elevated pulmonary artery pres- sure in untreated and desensitized (post iloprost infusion) lungs Figure 2
Dose effect curve of the PDE3 inhibitor motapizone or PDE4 inhibitor rolipram on U46619-elevated pulmo-
nary artery pressure in untreated and desensitized (post iloprost infusion) lungs. Motapizone and rolipram dose-
dependently reduced the elevated pulmonary artery pressure. There was no change in the dose response curve when applying 
identical doses of motapizone 240 min after iloprost infusion. (A) The decrease in pulmonary artery pressure (ΔPAP, as 
decrease of U46619-induced pulmonary hypertension) in response to motapizone or (B) rolipram (concentrations related to 
the recirculating perfusate) is given. (mean ± SEM of four independent experiments each; SEM bars are not included when 
smaller than symbol). *: p < 0.05 as compared to U46619-elevated pulmonary artery pressure.Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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human pulmonary artery tissue) has been demonstrated
[44]. There is strong evidence of PDE activation and
upregulation in response to intracellular elevation of
cAMP. It has been shown recently that cyclic AMP upreg-
ulates isoforms of PDE4 in airway smooth muscle cells
[45], monocytes [46], endothelial cells [47] and Jurkat T-
cells [48]. In addition, short term activation (phosphor-
ylation) of PDE4 via PKA was demonstrated by treatment
of cells with forskolin, a stimulator of adenylate cyclase
[49]. Furthermore, treatment of rats with 7-oxo-prostacy-
clin resulted in a significant increase in PDE4 activity,
which attenuated the elevation of isoprenaline-induced
cAMP levels as well as the contractile force development
in a Langedorff-heart preparation [50]. Similar results
were obtained for PDE3 which has been shown to be reg-
ulated on the level of activity [48] and expression [32] by
increased cAMP levels. In the current study, we employed
motapizone and rolipram, selective inhibitors of PDE3
and PDE4, respectively and performed dose response
studies on vasodilation in normal and desensitized (ilo-
prost-treated) isolated rabbit lungs. As reported earlier,
these PDE inhibitors are potent pulmonary vasodilators
[51] and we found no shift in the dose response curve in
desensitized lungs. Thus, there is no evidence of increased
PDE activity in iloprost-treated isolated rabbit lungs.
Desensitization is not dependant on adenylate cyclase 
activity
We employed forskolin as direct activator of adenylate
cyclase and performed dose response studies on pulmo-
nary vasodilation in isolated rabbit lungs. The response to
forskolin in the desensitized (iloprost-treated) organs
Effect of inhaled iloprost on U46619-elevated pulmonary artery pressure in untreated and desensitized (post iloprost infusion)  lungs Figure 3
Effect of inhaled iloprost on U46619-elevated pulmonary artery pressure in untreated and desensitized (post 
iloprost infusion) lungs. Inhalation of aerosolized iloprost for 10 min (deposited dose 75 ng) resulted in a significant reduc-
tion of the U46619-induced pulmonary hypertension, with PAP values decreasing by a mean of 6.3 mmHg. The vasodilatory 
potency of inhaled iloprost was completely lost in the desensitization group (iloprost infusion for 240 min). *: p < 0.05 as com-
pared to U46619-elevated pulmonary artery pressure.Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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remained intact (and seemed to be slightly increased),
indicating no regulation of adenylate cyclase. Similar
results were obtained in rats chronically treated with
albuterol in which acetylcholine (ACh)-induced bron-
choconstriction was reversible by forskolin, but not by
albuterol itself, suggesting that the intracellular site of
desensitization is upstream of adenylate cyclase [27].
Moreover, the cAMP production of iloprost-pretreated
rabbit pulmonary smooth muscle cells in response to for-
skolin was also not significantly reduced, except in 24
hours of iloprost-pretreated group (to 75% of control).
This is quite contrary to iloprost responses, where a signif-
icantly reduced cAMP levels (to 25% of control) was
observed, thereby excluding the down-regulation of ade-
nylate cyclase as a possible reason for reduced cAMP for-
mation after continuous stimulation of cells with iloprost.
In this context, desensitization of IP receptors by iloprost
may possibly explained by its direct influence on the
receptor, a mechanism upstream of adenylate cyclases.
This involves rapid receptor phosphorylation, which
results in uncoupling of receptor-G protein interactions
and subsequent receptor internalization. These events
result in a diminished response to agonist [26]. This may
also be due to preferential reduction of domain-bound
pool of the cognate Gproteins GsαL and GsαS [52].
On the other hand, iloprost induced vasorelaxation
responses may also be via cAMP-independent manner.
Consistent with the observation, PGI2 analogues iloprost
Dose effect curve of the adenylate cyclase activator forskolin on U46619-elevated pulmonary artery pressure in untreated and  desensitized (post iloprost infusion) lungs Figure 4
Dose effect curve of the adenylate cyclase activator forskolin on U46619-elevated pulmonary artery pressure 
in untreated and desensitized (post iloprost infusion) lungs. Forskolin dose-dependently reduced the elevated pulmo-
nary artery pressure. There was no change in the dose response curve when applying identical doses of forskolin 240 min after 
iloprost infusion. The decrease in pulmonary artery pressure (ΔPAP, as decrease of U46619-induced pulmonary hypertension) 
in response to forskolin (concentrations related to the recirculating perfusate) is given (mean ± SEM of 4 independent experi-
ments each; SEM bars are not included when smaller than symbol). *: p < 0.05 as compared to U46619-elevated pulmonary 
artery pressure.Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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were shown to activate MaxiK and KIR channel and subse-
quent vasorelaxation through a cAMP-independent, G(s)-
protein mediated mechanism in vascular smooth muscle
cells [53,54]. Concomitantly in guinea-pig aorta, cyclic
AMP-dependent and -independent pathways were
recently proposed to underlie the relaxation induced by
the PGI2 analogues, iloprost and Beraprost [55-57]. In
contrast, in rat tail artery, it is thought that channel phos-
phorylation by cyclic AMP-dependent PKA is responsible
for the MaxiK channel-mediated vascular relaxation due
to IP receptor stimulation by iloprost [58,59]. This is well
in line with investigations in human fibroblasts, where
cells were challenged at any time point of iloprost pre-
treatment with forskolin and fully maintained their cAMP
response [30]. In contrast, Sobolewski et al., demon-
strated in rat pulmonary smooth muscle cells (PSMCs)
which were exposed to cicaprost, another PGI2 analogue,
a significant reduction in forskolin-induced cAMP pro-
duction [60] as well as a decrease in adenylate cyclase iso-
form 2 and 5/6 expression after one hour of exposure to
this prostanoid. However, both isoforms were expressed
at control levels when PSMCs were incubated for longer
time periods with cicaprost. It is possible that the agonists
employed, as well as species differences are responsible
for these conflicting data.
Iloprost influences the EP1 receptor in addition to the IP 
receptor
It is well known that iloprost, the clinically approved
compound for treatment of thromboangiitis obliterans
[20] and pulmonary arterial hypertension [5], is not
highly selective for the IP receptor but also activates the
Influence of iloprost infusion and its combination with AH 6809 and BIM on U46619-elicited pulmonary hypertension Figure 5
Influence of iloprost infusion and its combination with AH 6809 and BIM on U46619-elicited pulmonary hyper-
tension. Pulmonary artery pressure (PAP) is given (mean ± SEM of 4 independent experiments each, SEM bars are missing 
when enclosed by the symbol). (A) The prostaglandin E1 receptor antagonist AH 6809 alone or in combination with iloprost 
(pre-applied followed by an iloprost infusion). (B) The PKC inhibitor BIM alone or in combination with iloprost (pre-applied 
followed by an iloprost infusion).Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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EP1receptor which is coupled to Gq and signals via IP3
generation and increased intracellular calcium (Ca2+)
[61]. To investigate the effects of possible involvement of
the EP1receptor we employed the EP1receptor antagonist
AH 6809 and found a dramatic increase in the efficacy of
intravenous iloprost. In contrary, the AH 6809 applica-
tion alone had no effect on U46619-induced tension.
Thus, the agonistic effects on EP1receptor explain the dif-
ferences between iloprost and selective IP agonists in inhi-
bition of smooth muscle cell response [26,40].
PKC inhibition and IP receptor desensitization
There is evidence that the initial desensitization process is
dependent on phosphorylation of the IP receptor by PKC
[41,62]. After phosphorylation, the IP receptor is seques-
tered to clathrin-coated vesicles and by a dynamin-
dependant process internalized into endosomes [41]. This
receptor sequestration is, unlike desensitization, PKC-
independent [27] and a time of approximately 18 h is
needed for a resensitization in human fibroblasts [27,30].
However, several studies including our work employed
inhibitors of PKC (GF-109203X, BIM) and could not or
could only partially prevent receptor desensitization, sug-
gesting a minor role of PKC in the desensitization process.
In conclusion, this study demonstrates for the first time in
an intact lung model that the PGI2 analogue iloprost
caused desensitization of the IP receptor within 2 to 3
hours, resulting in complete loss of responsiveness after
this time period. Desensitization was not due to increased
PDE activity or loss of adenylate cyclase activity, but may
involve PKC function and co-stimulation of the EP1
receptor in addition to the IP receptor by this PGI2 ana-
logue.
Influence of iloprost infusion and its combination with AH 6809 and BIM on the area under the curve of the U46619-elicited  pulmonary hypertension Figure 6
Influence of iloprost infusion and its combination with AH 6809 and BIM on the area under the curve of the 
U46619-elicited pulmonary hypertension. Area under the curve (AUC) is given (mean ± SEM of 4 independent experi-
ments each). The AUC was calculated by standard techniques and is given as mmHg × min. **: p < 0.01; ***: p < 0.001 as com-
pared to AUC of sole iloprost infusion.Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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Prostacyclin receptor (IP) desensitization in rabbit pulmonary smooth muscle cells Figure 7
Prostacyclin receptor (IP) desensitization in rabbit pulmonary smooth muscle cells. Cells were continuously stim-
ulated with 100 nM iloprost for the indicated preincubation times. cAMP response to iloprost (100 nM) or forskolin (10 μM) 
was assayed in these cells and is given as a percent of the non-desensitized control. Values are expressed as mean ± SEM of 
three independent experiments performed in triplicate. *: p < 0.05; ***: p < 0.001 as compared to non-desensitized control.Respiratory Research 2007, 8:4 http://respiratory-research.com/content/8/1/4
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